Press releases
LIDDS Delårsrapport april – juni 2019 LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 LIDDS: Anja Peters becomes new CFO of LIDDS LIDDS continues to grow with new hire to manage pre-clinical trialsCompany Analysis
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2019-08-29 LIDDS Delårsrapport april – juni 2019
- 2019-08-28 LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
- 2019-08-19 LIDDS: Anja Peters becomes new CFO of LIDDS
- 2019-06-18 LIDDS continues to grow with new hire to manage pre-clinical trials
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
